Search

Your search keyword '"Pollicino, T"' showing total 366 results
Start Over Author "Pollicino, T"
366 results on '"Pollicino, T"'

1. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

Author

Brancaccio, G, Coco, B, Nardi, A, Quaranta, M, Tosti, M, Ferrigno, L, Cacciola, I, Messina, V, Chessa, L, Morisco, F, Milella, M, Barbaro, F, Ciancio, A, Russo, F, Coppola, N, Blanc, P, Claar, E, Verucchi, G, Puoti, M, Zignego, A, Chemello, L, Madonia, S, Fagiuoli, S, Marzano, A, Ferrari, C, Lampertico, P, Di Marco, V, Craxì, A, Santantonio, T, Raimondo, G, Brunetto, M, Gaeta, G, Kondili, L, Pasulo, L, Coppola, C, Pisano, F, Romano, M, Porcu, C, Bottalico, I, Cossiga, V, Tata, X, Sagnelli, C, Pierotti, P, Degasperi, E, Rosato, V, Badia, L, Ieluzzi, D, Monti, M, Bavetta, M, Cavalletto, L, Toniutto, P, Fornasiere, E, Colecchia, A, Ferrarese, A, Nardone, G, Rocco, A, Viganò, M, Foschi, F, Conti, F, Morsica, G, Salpietro, S, Torti, C, Costa, C, Federico, A, Dallio, M, Giorgini, A, Anselmo, M, De Leo, P, Zaltron, S, Cambianica, A, Piscaglia, F, Serio, I, Schivazappa, S, Mastroianni, A, Chidichimo, L, Massari, M, Mazzaro, C, Marrone, A, D'Amore, F, D'Offizi, G, Licata, A, Niro, G, Pollicino, T, Aghemo, A, Brancaccio G., Coco B., Nardi A., Quaranta M. G., Tosti M. E., Ferrigno L., Cacciola I., Messina V., Chessa L., Morisco F., Milella M., Barbaro F., Ciancio A., Russo F. P., Coppola N., Blanc P., Claar E., Verucchi G., Puoti M., Zignego A. L., Chemello L., Madonia S., Fagiuoli S., Marzano A., Ferrari C., Lampertico P., Di Marco V., Craxì A., Santantonio T. A., Raimondo G., Brunetto M. R., Gaeta G. B., Kondili L. A., Pasulo L., Coppola C., Pisano F., Romano M., Porcu C., Bottalico I. F., Cossiga V., Tata X., Sagnelli C., Pierotti P., Degasperi E., Rosato V., Badia L., Ieluzzi D., Monti M., Bavetta M. G., Cavalletto L., Toniutto P., Fornasiere E., Colecchia A., Ferrarese A., Nardone G., Rocco A., Viganò M., Foschi F. G., Conti F., Morsica G., Salpietro S., Torti C., Costa C., Federico A., Dallio M., Giorgini A., Anselmo M., De Leo P., Zaltron S., Cambianica A., Piscaglia F., Serio I., Schivazappa S., Mastroianni A., Chidichimo L., Massari M., Mazzaro C., Marrone A., D'Amore F. M., D'Offizi G., Licata A., Niro G. A., Pollicino T., Aghemo A., Brancaccio, G, Coco, B, Nardi, A, Quaranta, M, Tosti, M, Ferrigno, L, Cacciola, I, Messina, V, Chessa, L, Morisco, F, Milella, M, Barbaro, F, Ciancio, A, Russo, F, Coppola, N, Blanc, P, Claar, E, Verucchi, G, Puoti, M, Zignego, A, Chemello, L, Madonia, S, Fagiuoli, S, Marzano, A, Ferrari, C, Lampertico, P, Di Marco, V, Craxì, A, Santantonio, T, Raimondo, G, Brunetto, M, Gaeta, G, Kondili, L, Pasulo, L, Coppola, C, Pisano, F, Romano, M, Porcu, C, Bottalico, I, Cossiga, V, Tata, X, Sagnelli, C, Pierotti, P, Degasperi, E, Rosato, V, Badia, L, Ieluzzi, D, Monti, M, Bavetta, M, Cavalletto, L, Toniutto, P, Fornasiere, E, Colecchia, A, Ferrarese, A, Nardone, G, Rocco, A, Viganò, M, Foschi, F, Conti, F, Morsica, G, Salpietro, S, Torti, C, Costa, C, Federico, A, Dallio, M, Giorgini, A, Anselmo, M, De Leo, P, Zaltron, S, Cambianica, A, Piscaglia, F, Serio, I, Schivazappa, S, Mastroianni, A, Chidichimo, L, Massari, M, Mazzaro, C, Marrone, A, D'Amore, F, D'Offizi, G, Licata, A, Niro, G, Pollicino, T, Aghemo, A, Brancaccio G., Coco B., Nardi A., Quaranta M. G., Tosti M. E., Ferrigno L., Cacciola I., Messina V., Chessa L., Morisco F., Milella M., Barbaro F., Ciancio A., Russo F. P., Coppola N., Blanc P., Claar E., Verucchi G., Puoti M., Zignego A. L., Chemello L., Madonia S., Fagiuoli S., Marzano A., Ferrari C., Lampertico P., Di Marco V., Craxì A., Santantonio T. A., Raimondo G., Brunetto M. R., Gaeta G. B., Kondili L. A., Pasulo L., Coppola C., Pisano F., Romano M., Porcu C., Bottalico I. F., Cossiga V., Tata X., Sagnelli C., Pierotti P., Degasperi E., Rosato V., Badia L., Ieluzzi D., Monti M., Bavetta M. G., Cavalletto L., Toniutto P., Fornasiere E., Colecchia A., Ferrarese A., Nardone G., Rocco A., Viganò M., Foschi F. G., Conti F., Morsica G., Salpietro S., Torti C., Costa C., Federico A., Dallio M., Giorgini A., Anselmo M., De Leo P., Zaltron S., Cambianica A., Piscaglia F., Serio I., Schivazappa S., Mastroianni A., Chidichimo L., Massari M., Mazzaro C., Marrone A., D'Amore F. M., D'Offizi G., Licata A., Niro G. A., Pollicino T., and Aghemo A.

Abstract

Objectives: The study measures trends in the profile of patients with chronic hepatitis B virus linked to care in Italy. Methods: A cross-sectional, multicenter, observational cohort (PITER cohort) of consecutive patients with hepatitis B surface antigen (HBsAg) over the period 2019-2021 from 46 centers was evaluated. The reference was the MASTER cohort collected over the years 2012-2015. Standard statistical methods were used. Results: The PITER cohort enrolled 4583 patients, of whom 21.8% were non-Italian natives. Compared with those in MASTER, the patients were older and more often female. The prevalence of hepatitis B e antigen (HBeAg) declined (7.2% vs 12.3; P <0.0001) and that of anti-hepatitis D virus (HDV) remained stable (9.3% vs 8.3%). In both cohorts, about 25% of the patients had cirrhosis, and those in the PITER cohort were older. HBeAg-positive was 5.0% vs 12.6% (P <0.0001) and anti-HDV positive 24.8% vs 17.5% (P <0.0017). In the logistic model, the variables associated with cirrhosis were anti-HDV-positive (odds ratio = 10.08; confidence interval 7.63-13.43), age, sex, and body mass index; the likelihood of cirrhosis was reduced by 40% in the PITER cohort. Among non-Italians, 12.3% were HBeAg-positive (vs 23.4% in the MASTER cohort; P <0.0001), and 12.3% were anti-HDV-positive (vs 11.1%). Overall, the adherence to the European Association for the Study of the Liver recommendations for antiviral treatment increased over time. Conclusion: Chronic hepatitis B virus infection appears to be in the process of becoming under control in Italy; however, HDV infection is still a health concern in patients with cirrhosis and in migrants.

Published
2023

4. Hepatitis delta virus (hdv) replication through hbv integrants in hcc recurrence after liver transplantation.

Author

Di Marco, L., De Maria, N., Pivetti, A., Colecchia, A., Romanzi, A., Spallanzani, A., Guaraldi, G., Dolci, G., Ciusa, G., Di Benedetto, F., Magistri, P., Di Sandro, S., Degasperi, E., Anolli, M.P., Lampertico, P., Giosa, D., Lombardo, D., Raimondo, G., and Pollicino, T.

Abstract

A PWID man, HCV/HBV-HDV/HIV-infected, underwent liver transplantation (LT) for HCC in 2012 at the age of 52 years. HCC tissue showed high HDV-RNA (88,400 copies/cell), low total HBV-DNA (0.00001 c/c), and HBVcccDNA0.00008 c/c), without detectable HBV-RNA. High-throughput HBV integration sequencing (HBIS) identified 657 HBV integration sites.HBV integrants were predominantly represented by HBx gene sequences. After LT, Tacrolimus, Bictegravir/Emtricitabine/TAF, and anti-HBs immunoglobulin were administered, yielding HBsAg, HDV-RNA, and HCV-RNA negativity. In 2018, HBsAg reversion was observed with undetectable HBV-DNA and HDV-RNA >19,000 c/ml. In 2019, HDV-related hepatitis occurred. Intrahepatic HBcAg, HBsAgHBV DNA, HBVcccDNA, and HBV-RNA were undetectable. HDV RNA concentrations were very high in the liver (3,920,000 c/c) but low in the serum (214 IU/mL). CT scan (CTs) suspected an isolated HCC recurrence in the left adrenal gland, confirmed by adrenalectomy. Real-time PCR in the tumor from the adrenal gland revealed high levels of HDV RNA (5.5 c/c) but low levels of HBV DNA (0.00009 c/c) and HBVcccDNA (0.00001 c/c). HBV RNA was undetectable. HBIS identified 3497 HBV integrations, most of which included HBs gene sequences. After adrenalectomy, HBsAg and HDV-RNA became undetectable. Anti-HBs immunoglobulin was continued with Everolimus. In 2021, CTs showed two HCC nodules in the liver and one in the right adrenal gland. TACE was performed, and TKI therapy was started. In 2023, new HDV hepatitis occurred, with HDV-RNA>3,631,360 UI/ml and HBV-DNA <10UI/ml. For the progression of HCC, RFA on the right adrenal gland was performed, and Bulevirtide was started. After 3 months, HDV-RNA was 48,638 c/ml, and transaminases were normal. This case demonstrates HDV replication in extrahepatic HCC recurrence, despite low levels of HBVcccDNA. The decreased HDV RNA levels after RFA and BLV therapy suggest that HCC metastases may serve as HBsAg production sites following HBV integration. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

Author

Di Maio, V, Barbaliscia, S, Teti, E, Fiorentino, G, Milana, M, Paolucci, S, Pollicino, T, Morsica, G, Starace, M, Bruzzone, B, Gennari, W, Micheli, V, Yu La Rosa, K, Foroghi, L, Calvaruso, V, Lenci, I, Polilli, E, Babudieri, S, Aghemo, A, Raimondo, G, Sarmati, L, Coppola, N, Pasquazzi, C, Baldanti, F, Parruti, G, Perno, C, Angelico, M, Craxi, A, Andreoni, M, Ceccherini-Silberstein, F, Andreone, P, Aragri, M, Bertoli, A, Boeri, E, Brancaccio, G, Brunetto, M, Callegaro, A, Cenderello, G, Cento, V, Ciaccio, A, Ciancio, A, Cuomo, N, De Santis, A, Di Biagio, A, Di Marco, V, Di Perri, G, Di Stefano, M, Gaeta, G, Ghisetti, V, Gulminetti, R, Lampertico, P, Landonio, S, Lichtner, M, Lleo, A, Maida, I, Marenco, S, Masetti, C, Mastroianni, C, Minichini, C, Milano, E, Monno, L, Novati, S, Pace Palitti, V, Paternoster, C, Pellicelli, A, Pieri, A, Puoti, M, Rizzardini, G, Ruggiero, T, Rossetti, B, Sangiovanni, V, Santantonio, T, Taliani, G, Toniutto, P, Vullo, V, Zazzi, M, Di Maio V. C., Barbaliscia S., Teti E., Fiorentino G., Milana M., Paolucci S., Pollicino T., Morsica G., Starace M., Bruzzone B., Gennari W., Micheli V., Yu La Rosa K., Foroghi L., Calvaruso V., Lenci I., Polilli E., Babudieri S., Aghemo A., Raimondo G., Sarmati L., Coppola N., Pasquazzi C., Baldanti F., Parruti G., Perno C. F., Angelico M., Craxi A., Andreoni M., Ceccherini-Silberstein F., Andreone P., Aragri M., Bertoli A., Boeri E., Brancaccio G., Brunetto M., Callegaro A. P., Cenderello G., Cento V., Ciaccio A., Ciancio A., Cuomo N., De Santis A., Di Biagio A., Di Marco V., Di Perri G., Di Stefano M. A., Gaeta G. B., Ghisetti V., Gulminetti R., Lampertico P., Landonio S., Lichtner M., Lleo A., Maida I., Marenco S., Masetti C., Mastroianni C., Minichini C., Milano E., Monno L., Novati S., Pace Palitti V., Paternoster C., Pellicelli A., Pieri A., Puoti M., Rizzardini G., Ruggiero T., Rossetti B., Sangiovanni V., Santantonio T., Taliani G., Toniutto P., Vullo V., Zazzi M., Di Maio, V, Barbaliscia, S, Teti, E, Fiorentino, G, Milana, M, Paolucci, S, Pollicino, T, Morsica, G, Starace, M, Bruzzone, B, Gennari, W, Micheli, V, Yu La Rosa, K, Foroghi, L, Calvaruso, V, Lenci, I, Polilli, E, Babudieri, S, Aghemo, A, Raimondo, G, Sarmati, L, Coppola, N, Pasquazzi, C, Baldanti, F, Parruti, G, Perno, C, Angelico, M, Craxi, A, Andreoni, M, Ceccherini-Silberstein, F, Andreone, P, Aragri, M, Bertoli, A, Boeri, E, Brancaccio, G, Brunetto, M, Callegaro, A, Cenderello, G, Cento, V, Ciaccio, A, Ciancio, A, Cuomo, N, De Santis, A, Di Biagio, A, Di Marco, V, Di Perri, G, Di Stefano, M, Gaeta, G, Ghisetti, V, Gulminetti, R, Lampertico, P, Landonio, S, Lichtner, M, Lleo, A, Maida, I, Marenco, S, Masetti, C, Mastroianni, C, Minichini, C, Milano, E, Monno, L, Novati, S, Pace Palitti, V, Paternoster, C, Pellicelli, A, Pieri, A, Puoti, M, Rizzardini, G, Ruggiero, T, Rossetti, B, Sangiovanni, V, Santantonio, T, Taliani, G, Toniutto, P, Vullo, V, Zazzi, M, Di Maio V. C., Barbaliscia S., Teti E., Fiorentino G., Milana M., Paolucci S., Pollicino T., Morsica G., Starace M., Bruzzone B., Gennari W., Micheli V., Yu La Rosa K., Foroghi L., Calvaruso V., Lenci I., Polilli E., Babudieri S., Aghemo A., Raimondo G., Sarmati L., Coppola N., Pasquazzi C., Baldanti F., Parruti G., Perno C. F., Angelico M., Craxi A., Andreoni M., Ceccherini-Silberstein F., Andreone P., Aragri M., Bertoli A., Boeri E., Brancaccio G., Brunetto M., Callegaro A. P., Cenderello G., Cento V., Ciaccio A., Ciancio A., Cuomo N., De Santis A., Di Biagio A., Di Marco V., Di Perri G., Di Stefano M. A., Gaeta G. B., Ghisetti V., Gulminetti R., Lampertico P., Landonio S., Lichtner M., Lleo A., Maida I., Marenco S., Masetti C., Mastroianni C., Minichini C., Milano E., Monno L., Novati S., Pace Palitti V., Paternoster C., Pellicelli A., Pieri A., Puoti M., Rizzardini G., Ruggiero T., Rossetti B., Sangiovanni V., Santantonio T., Taliani G., Toniutto P., Vullo V., and Zazzi M.

Abstract

Aim: This study aimed to investigate the role of resistance-associated substitutions (RASs) to direct-acting-antivirals (DAAs) in HCV genotype 3 (GT3). Methods: Within the Italian VIRONET-C network, a total of 539 GT3-infected patients (417 DAA-naïve and 135 DAA-failures, of them, 13 at both baseline and failure) were analysed. Sanger sequencing of NS3/NS5A/NS5B was performed following home-made protocols. Results: The majority of patients were male (79.4%), 91.4% were injection drug users, 49.3% were cirrhotic and 13.9% were HIV co-infected. Phylogenetic analysis classified sequences as GT3a-b-g-h (98%-0.4%-0.2%-1.2%) respectively. Overall, 135 patients failed a DAA regimen: sofosbuvir (SOF)/daclatasvir (DCV) or velpatasvir (VEL)±ribavirin (RBV) (N = 91/15) and glecaprevir (G)/pibrentasvir (P) (N = 9). Moreover, 14.8% of patients were treated with suboptimal regimens for GT3: 3D ± RBV (Paritaprevir/r + Ombitasvir+Dasabuvir, N = 15), SOF + Simeprevir (SIM) (N = 1) or SOF/Ledipasvir (LDV) ± RBV (N = 4). RAS prevalence was 15.8% in DAA-naïve patients. At failure, 81.5% patients showed at least one RAS: 11/25 (44.0%) in NS3, 109/135 (80.7%) in NS5A, 7/111 (6.3%) in NS5B SOF-failures. In NS5A-failures, Y93H RAS was the most prevalent (68.5% vs 5.1% DAA-naïve, P <.001) followed by A30K (12.7% vs 2.8% in DAA-naïve, P <.001). Analysing baseline samples, a higher prevalence of NS5A-RASs was observed before treatment in DAA-failures (5/13, 38.5%) vs DAA-naïves (61/393, 15.5%, P =.04). Regarding 228 DAA-naïve patients with an available outcome, 93.9% achieved a SVR. Interestingly, patients with baseline Y93H and/or A30K had SVR rate of 72.2% vs 95.7% for patients without NS5A-RASs (P =.002). Conclusions: In this real-life GT3 cohort, the majority of failures harboured resistant variants carrying NS5A-RASs, the most frequent being Y93H. The presence of natu

Published
2021

7. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

Author

Di Maio, V. C., Barbaliscia, S., Teti, E., Fiorentino, G., Milana, M., Paolucci, S., Pollicino, T., Morsica, G., Starace, M., Bruzzone, B., Gennari, W., Micheli, V., Yu La Rosa, K., Foroghi, L., Calvaruso, V., Lenci, I., Polilli, E., Babudieri, S., Aghemo, A., Raimondo, G., Sarmati, L., Coppola, N., Pasquazzi, C., Baldanti, F., Parruti, G., Perno, C. F., Angelico, M., Craxi, A., Andreoni, M., Ceccherini-Silberstein, F., Andreone, P., Aragri, M., Bertoli, A., Boeri, E., Brancaccio, G., Brunetto, M., Callegaro, A. P., Cenderello, G., Cento, V., Ciaccio, A., Ciancio, A., Cuomo, N., De Santis, A., Di Biagio, A., Di Marco, V., Di Perri, G., Di Stefano, M. A., Gaeta, G. B., Ghisetti, V., Gulminetti, R., Lampertico, P., Landonio, S., Lichtner, M., Lleo, A., Maida, I., Marenco, S., Masetti, C., Mastroianni, C., Minichini, C., Milano, E., Monno, L., Novati, S., Pace Palitti, V., Paternoster, C., Pellicelli, A., Pieri, A., Puoti, M., Rizzardini, G., Ruggiero, T., Rossetti, B., Sangiovanni, V., Santantonio, T., Taliani, G., Toniutto, P., Vullo, V., Zazzi, M., Di Maio, V, Barbaliscia, S, Teti, E, Fiorentino, G, Milana, M, Paolucci, S, Pollicino, T, Morsica, G, Starace, M, Bruzzone, B, Gennari, W, Micheli, V, Yu La Rosa, K, Foroghi, L, Calvaruso, V, Lenci, I, Polilli, E, Babudieri, S, Aghemo, A, Raimondo, G, Sarmati, L, Coppola, N, Pasquazzi, C, Baldanti, F, Parruti, G, Perno, C, Angelico, M, Craxi, A, Andreoni, M, Ceccherini-Silberstein, F, Andreone, P, Aragri, M, Bertoli, A, Boeri, E, Brancaccio, G, Brunetto, M, Callegaro, A, Cenderello, G, Cento, V, Ciaccio, A, Ciancio, A, Cuomo, N, De Santis, A, Di Biagio, A, Di Marco, V, Di Perri, G, Di Stefano, M, Gaeta, G, Ghisetti, V, Gulminetti, R, Lampertico, P, Landonio, S, Lichtner, M, Lleo, A, Maida, I, Marenco, S, Masetti, C, Mastroianni, C, Minichini, C, Milano, E, Monno, L, Novati, S, Pace Palitti, V, Paternoster, C, Pellicelli, A, Pieri, A, Puoti, M, Rizzardini, G, Ruggiero, T, Rossetti, B, Sangiovanni, V, Santantonio, T, Taliani, G, Toniutto, P, Vullo, V, Zazzi, M, Di Maio, Vc, Perno, Cf, Craxì, A, Di Maio V.C., Barbaliscia S., Teti E., Fiorentino G., Milana M., Paolucci S., Pollicino T., Morsica G., Starace M., Bruzzone B., Gennari W., Micheli V., Yu La Rosa K., Foroghi L., Calvaruso V., Lenci I., Polilli E., Babudieri S., Aghemo A., Raimondo G., Sarmati L., Coppola N., Pasquazzi C., Baldanti F., Parruti G., Perno C.F., Angelico M., Craxi A., Andreoni M., Ceccherini-Silberstein F., Andreone P., Aragri M., Bertoli A., Boeri E., Brancaccio G., Brunetto M., Callegaro A.P., Cenderello G., Cento V., Ciaccio A., Ciancio A., Cuomo N., De Santis A., Di Biagio A., Di Marco V., Di Perri G., Di Stefano M.A., Gaeta G.B., Ghisetti V., Gulminetti R., Lampertico P., Landonio S., Lichtner M., Lleo A., Maida I., Marenco S., Masetti C., Mastroianni C., Minichini C., Milano E., Monno L., Novati S., Pace Palitti V., Paternoster C., Pellicelli A., Pieri A., Puoti M., Rizzardini G., Ruggiero T., Rossetti B., Sangiovanni V., Santantonio T., Taliani G., Toniutto P., Vullo V., and Zazzi M.

Subjects
Male, Sofosbuvir, Sustained Virologic Response, Drug Resistance, Hepacivirus, Viral Nonstructural Proteins, Gastroenterology, Settore MED/06, direct-acting antivirals, failure, genotype 3, HCV, resistance, chemistry.chemical_compound, 0302 clinical medicine, Medicine, Viral, Chronic, Phylogeny, Dasabuvir, hcv, virus diseases, Hepatitis C, Pibrentasvir, Italy, 030220 oncology & carcinogenesis, Combination, Drug Therapy, Combination, 030211 gastroenterology & hepatology, Female, medicine.drug, Ledipasvir, medicine.medical_specialty, Daclatasvir, Genotype, Antiviral Agents, Drug Resistance, Viral, Humans, Hepatitis C, Chronic, 03 medical and health sciences, Drug Therapy, Internal medicine, Antiviral Agent, direct-acting antiviral, Hepaciviru, Hepatology, business.industry, Viral Nonstructural Protein, Glecaprevir, direct acting antivirals, Regimen, chemistry, Paritaprevir, business
Abstract

Aim: This study aimed to investigate the role of resistance-associated substitutions (RASs) to direct-acting-antivirals (DAAs) in HCV genotype 3 (GT3). Methods: Within the Italian VIRONET-C network, a total of 539 GT3-infected patients (417 DAA-naïve and 135 DAA-failures, of them, 13 at both baseline and failure) were analysed. Sanger sequencing of NS3/NS5A/NS5B was performed following home-made protocols. Results: The majority of patients were male (79.4%), 91.4% were injection drug users, 49.3% were cirrhotic and 13.9% were HIV co-infected. Phylogenetic analysis classified sequences as GT3a-b-g-h (98%-0.4%-0.2%-1.2%) respectively. Overall, 135 patients failed a DAA regimen: sofosbuvir (SOF)/daclatasvir (DCV) or velpatasvir (VEL)±ribavirin (RBV) (N=91/15) and glecaprevir (G)/pibrentasvir (P) (N=9). Moreover, 14.8% of patients were treated with suboptimal regimens for GT3: 3D±RBV (Paritaprevir/r+Ombitasvir+Dasabuvir, N=15), SOF+Simeprevir (SIM) (N=1) or SOF/Ledipasvir (LDV)±RBV (N=4). RAS prevalence was 15.8% in DAA-naïve patients. At failure, 81.5% patients showed at least one RAS: 11/25 (44.0%) in NS3, 109/135 (80.7%) in NS5A, 7/111 (6.3%) in NS5B SOF-failures. In NS5A-failures, Y93H RAS was the most prevalent (68.5% vs 5.1% DAA-naïve, P&nbsp

Published
2021

9. A new high-throughput HBV integration sequencing approach shows that mitochondrial DNA is frequently targeted by virus integration in liver cells with active HBV replication

Author

Giosa, D., primary, Lombardo, D., additional, Musolino, C., additional, Chines, V., additional, Raffa, G., additional, Casuscelli di Tocco, F., additional, D'Aliberti, D., additional, Saitta, C., additional, Alibrandi, A., additional, Aiese Cigliano, R., additional, Romeo, O., additional, Navarra, G., additional, Raimondo, G., additional, and Pollicino, T., additional

Published
2022
Full Text
View/download PDF

10. Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021

Author

Stefanelli, P., Trentini, F., Guzzetta, G., Marziano, V., Mammone, A., Schepisi, M. S., Poletti, P., Grane, C. M., Manica, M., del Manso, M., Andrianou, X., Ajelli, M., Rezza, G., Brusaferro, S., Merler, S., Di Martino, A., Ambrosio, L., Lo Presti, A., Fiore, S., Fabiani, C., Benedetti, E., Di Mario, G., Facchini, M., Puzelli, S., Calzoletti, L., Fontana, S., Venturi, G., Fortuna, C., Marsili, G., Amendola, A., Stuppia, L., Savini, G., Picerno, A., Lopizzo, T., Dell'Edera, D., Minchella, P., Greco, F., Viglietto, G., Atripaldi, L., Limone, A., D'Agaro, P., Licastro, D., Pongolini, S., Sambri, V., Dirani, G., Zannoli, S., Affanni, P., Colucci, M. E., Capobianchi, M. R., Icardi, G., Bruzzone, B., Lillo, F., Orsi, A., Pariani, E., Baldanti, F., Molecolare, U. V., Gismondo, M. R., Maggi, F., Caruso, A., Ceriotti, F., Boniotti, M. B., Barbieri, I., Bagnarelli, P., Menzo, S., Garofalo, S., Scutella, M., Pagani, E., Collini, L., Ghisetti, V., Brossa, S., Ru, G., Bozzetta, E., Chironna, M., Parisi, A., Rubino, S., Serra, C., Piras, G., Coghe, F., Vitale, F., Tramuto, F., Scalia, G., Palermo, C. I., Mancuso, G., Pollicino, T., Di Gaudio, F., Vullo, S., Reale, S., Cusi, M. G., Rossolini, G. M., Pistello, M., Mencacci, A., Camilloni, B., Severini, S., Di Benedetto, M., Terregino, C., Monne, I., Biscaro, V., Stefanelli P, Trentini F, Guzzetta G, Marziano V, Mammone A, Sane Schepisi M, Poletti P, Molina Grané C, Manica M, Del Manso M, Andrianou X, Ajelli M, Rezza G, Brusaferro S, Merler S, Vitale F, Tramuto F, Stefanelli P., Trentini F., Guzzetta G., Marziano V., Mammone A., Sane Schepisi M., Poletti P., Molina Grane C., Manica M., Del Manso M., Andrianou X., Ajelli M., Rezza G., Brusaferro S., Merler S., Sambri V, and (membro del COVID-19 National Microbiology Surveillance Study Group)

Subjects
Epidemiology, SARS-CoV-2, Public Health, Environmental and Occupational Health, COVID-19, co-circulation, lineage, SARS-CoV-2 variant of concern, transmissibility, Humans, Italy, Models, Theoretical, Settore MED/42 - Igiene Generale E Applicata, SARS-COV-2 VARIANT OF CONCERN, CO-CIRCULATION, LINEAGE, TRANSMISSIBILITY, HUMANS, ITALY, MODELS, THEORETICAL, COVID-19, SARS-COV-2, Theoretical, Models, Virology, Human
Abstract

Background Several SARS-CoV-2 variants of concern (VOC) have emerged through 2020 and 2021. There is need for tools to estimate the relative transmissibility of emerging variants of SARS-CoV-2 with respect to circulating strains. Aim We aimed to assess the prevalence of co-circulating VOC in Italy and estimate their relative transmissibility. Methods We conducted two genomic surveillance surveys on 18 February and 18 March 2021 across the whole Italian territory covering 3,243 clinical samples and developed a mathematical model that describes the dynamics of co-circulating strains. Results The Alpha variant was already dominant on 18 February in a majority of regions/autonomous provinces (national prevalence: 54%) and almost completely replaced historical lineages by 18 March (dominant across Italy, national prevalence: 86%). We found a substantial proportion of the Gamma variant on 18 February, almost exclusively in central Italy (prevalence: 19%), which remained similar on 18 March. Nationally, the mean relative transmissibility of Alpha ranged at 1.55–1.57 times the level of historical lineages (95% CrI: 1.45–1.66). The relative transmissibility of Gamma varied according to the assumed degree of cross-protection from infection with other lineages and ranged from 1.12 (95% CrI: 1.03–1.23) with complete immune evasion to 1.39 (95% CrI: 1.26–1.56) for complete cross-protection. Conclusion We assessed the relative advantage of competing viral strains, using a mathematical model assuming different degrees of cross-protection. We found substantial co-circulation of Alpha and Gamma in Italy. Gamma was not able to outcompete Alpha, probably because of its lower transmissibility.

Published
2022

11. Update of the statements on biology and clinical impact of occult hepatitis B virus infection

Author

Raimondo, G, Locarnini, S, Pollicino, T, Levrero, M, Zoulim, F, Lok, A, Allain, J, Berg, T, Bertoletti, A, Brunetto, M, Bruno, R, Chen, D, Coppola, N, Cornberg, M, Craxi, A, Dandri, M, Di Marco, V, Ferrari, C, Gaeta, G, Glebe, D, Guidotti, L, Kramvis, A, Lampertico, P, Li, C, Liang, J, Marzano, A, Michalak, T, Pawlotsky, J, Prati, D, Puoti, M, Samuel, D, Soriano, V, Squadrito, G, Sureau, C, Trepo, C, Yuen, M, Raimondo G., Locarnini S., Pollicino T., Levrero M., Zoulim F., Lok A. S., Allain J. -P., Berg T., Bertoletti A., Brunetto M. R., Bruno R., Chen D. -S., Coppola N., Cornberg M., Craxi A., Dandri M., Di Marco V., Ferrari C., Gaeta G. B., Glebe D., Guidotti L. G., Kramvis A., Lampertico P., Li C., Liang J., Marzano A., Michalak T. I., Pawlotsky J. -M., Prati D., Puoti M., Samuel D., Soriano V., Squadrito G., Sureau C., Trepo C., Yuen M. -F., Raimondo, G, Locarnini, S, Pollicino, T, Levrero, M, Zoulim, F, Lok, A, Allain, J, Berg, T, Bertoletti, A, Brunetto, M, Bruno, R, Chen, D, Coppola, N, Cornberg, M, Craxi, A, Dandri, M, Di Marco, V, Ferrari, C, Gaeta, G, Glebe, D, Guidotti, L, Kramvis, A, Lampertico, P, Li, C, Liang, J, Marzano, A, Michalak, T, Pawlotsky, J, Prati, D, Puoti, M, Samuel, D, Soriano, V, Squadrito, G, Sureau, C, Trepo, C, Yuen, M, Raimondo G., Locarnini S., Pollicino T., Levrero M., Zoulim F., Lok A. S., Allain J. -P., Berg T., Bertoletti A., Brunetto M. R., Bruno R., Chen D. -S., Coppola N., Cornberg M., Craxi A., Dandri M., Di Marco V., Ferrari C., Gaeta G. B., Glebe D., Guidotti L. G., Kramvis A., Lampertico P., Li C., Liang J., Marzano A., Michalak T. I., Pawlotsky J. -M., Prati D., Puoti M., Samuel D., Soriano V., Squadrito G., Sureau C., Trepo C., and Yuen M. -F.

Abstract

In October 2018 a large number of international experts with complementary expertise came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). The objectives of the workshop were to review the existing knowledge on OBI, to identify issues that require further investigation, to highlight both existing controversies and newly emerging perspectives, and ultimately to update the statements previously agreed in 2008. This paper represents the output from the workshop.

Published
2019

12. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

Author

Di Maio, V, Cento, V, Aragri, M, Paolucci, S, Pollicino, T, Coppola, N, Bruzzone, B, Ghisetti, V, Zazzi, M, Brunetto, M, Bertoli, A, Barbaliscia, S, Galli, S, Gennari, W, Baldanti, F, Raimondo, G, Perno, C, Ceccherini-Silberstein, F, Andreone, P, Andreoni, M, Angelico, M, Babudieri, S, Barbarini, G, Boccaccio, V, Boglione, L, Bolis, M, Bonora, S, Borghi, V, Brancaccio, G, Bruno, S, Cacciatore, P, Calvaruso, V, Caporaso, N, Ciaccio, A, Ciancio, A, Colombatto, P, Cozzolongo, R, Craxi, A, D'Ambrosio, C, D'Ettorre, G, De Luca, A, Di Biagio, A, Di Perri, G, Francioso, S, Gaeta, G, Giorgini, A, Grieco, A, Gubertini, G, Gulminetti, R, Lambiase, L, Lenci, I, Lichtner, M, Maida, I, Marenco, S, Marinaro, L, Maserati, R, Masetti, C, Melis, M, Meregalli, E, Micheli, V, Morisco, F, Niero, F, Nicolini, L, Palitti, V, Paoloni, M, Parruti, G, Pasquazzi, C, Pellicelli, A, Polilli, E, Ponti, M, Puoti, M, Rendina, M, Rizzardini, G, Rossetti, B, Ruggiero, T, Sangiovanni, V, Starace, M, Sticchi, L, Tarquini, P, Toniutto, P, Vullo, V, Di Maio V. C., Cento V., Aragri M., Paolucci S., Pollicino T., Coppola N., Bruzzone B., Ghisetti V., Zazzi M., Brunetto M., Bertoli A., Barbaliscia S., Galli S., Gennari W., Baldanti F., Raimondo G., Perno C. F., Ceccherini-Silberstein F., Andreone P., Andreoni M., Angelico M., Babudieri S., Barbarini G., Boccaccio V., Boglione L., Bolis M., Bonora S., Borghi V., Brancaccio G., Bruno S., Cacciatore P., Calvaruso V., Caporaso N., Ciaccio A., Ciancio A., Colombatto P., Cozzolongo R., Craxi A., D'Ambrosio C., D'Ettorre G., De Luca A., Di Biagio A., Di Perri G., Francioso S., Gaeta G. B., Giorgini A., Grieco A., Gubertini G., Gulminetti R., Lambiase L., Lenci I., Lichtner M., Maida I., Marenco S., Marinaro L., Maserati R., Masetti C., Melis M., Meregalli E., Micheli V., Morisco F., Niero F., Nicolini L. A., Palitti V. P., Paoloni M., Parruti G., Pasquazzi C., Pellicelli A., Polilli E., Ponti M. L., Puoti M., Rendina M., Rizzardini G., Rossetti B., Ruggiero T., Sangiovanni V., Starace M., Sticchi L., Tarquini P., Toniutto P., Vullo V., Di Maio, V, Cento, V, Aragri, M, Paolucci, S, Pollicino, T, Coppola, N, Bruzzone, B, Ghisetti, V, Zazzi, M, Brunetto, M, Bertoli, A, Barbaliscia, S, Galli, S, Gennari, W, Baldanti, F, Raimondo, G, Perno, C, Ceccherini-Silberstein, F, Andreone, P, Andreoni, M, Angelico, M, Babudieri, S, Barbarini, G, Boccaccio, V, Boglione, L, Bolis, M, Bonora, S, Borghi, V, Brancaccio, G, Bruno, S, Cacciatore, P, Calvaruso, V, Caporaso, N, Ciaccio, A, Ciancio, A, Colombatto, P, Cozzolongo, R, Craxi, A, D'Ambrosio, C, D'Ettorre, G, De Luca, A, Di Biagio, A, Di Perri, G, Francioso, S, Gaeta, G, Giorgini, A, Grieco, A, Gubertini, G, Gulminetti, R, Lambiase, L, Lenci, I, Lichtner, M, Maida, I, Marenco, S, Marinaro, L, Maserati, R, Masetti, C, Melis, M, Meregalli, E, Micheli, V, Morisco, F, Niero, F, Nicolini, L, Palitti, V, Paoloni, M, Parruti, G, Pasquazzi, C, Pellicelli, A, Polilli, E, Ponti, M, Puoti, M, Rendina, M, Rizzardini, G, Rossetti, B, Ruggiero, T, Sangiovanni, V, Starace, M, Sticchi, L, Tarquini, P, Toniutto, P, Vullo, V, Di Maio V. C., Cento V., Aragri M., Paolucci S., Pollicino T., Coppola N., Bruzzone B., Ghisetti V., Zazzi M., Brunetto M., Bertoli A., Barbaliscia S., Galli S., Gennari W., Baldanti F., Raimondo G., Perno C. F., Ceccherini-Silberstein F., Andreone P., Andreoni M., Angelico M., Babudieri S., Barbarini G., Boccaccio V., Boglione L., Bolis M., Bonora S., Borghi V., Brancaccio G., Bruno S., Cacciatore P., Calvaruso V., Caporaso N., Ciaccio A., Ciancio A., Colombatto P., Cozzolongo R., Craxi A., D'Ambrosio C., D'Ettorre G., De Luca A., Di Biagio A., Di Perri G., Francioso S., Gaeta G. B., Giorgini A., Grieco A., Gubertini G., Gulminetti R., Lambiase L., Lenci I., Lichtner M., Maida I., Marenco S., Marinaro L., Maserati R., Masetti C., Melis M., Meregalli E., Micheli V., Morisco F., Niero F., Nicolini L. A., Palitti V. P., Paoloni M., Parruti G., Pasquazzi C., Pellicelli A., Polilli E., Ponti M. L., Puoti M., Rendina M., Rizzardini G., Rossetti B., Ruggiero T., Sangiovanni V., Starace M., Sticchi L., Tarquini P., Toniutto P., and Vullo V.

Published
2018

13. Frequency of somatic mutations in TERT promoter, TP53 and CTNNB1 genes in patients with hepatocellular carcinoma from Southern Italy

Author

Lombardo, D., Saitta, C., Giosa, D., Di Tocco, F. C., Musolino, C., Caminiti, G., Chines, V., Franze, M. S., Alibrandi, A., Navarra, G., Raimondo, G., and Pollicino, T.

Subjects
Somatic mutations, Hepatocellular carcinoma, CTNNB1 gene, TP53 gene, TERT promoter, Activating protein 2 transcription factor, Activating protein 2 transcription factor, CTNNB1 gene, Hepatocellular carcinoma, Somatic mutations,TERT promoter, TP53 gene
Published
2020

17. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

Author

Barbaliscia, S., primary, Di Maio, V.C., additional, Fabeni, L., additional, Teti, E., additional, Paolucci, S., additional, Minichini, C., additional, Aragri, M., additional, Rosa, K. Yu La, additional, Carioti, L., additional, Pasquazzi, C., additional, Milana, M., additional, Foroghi, L., additional, Pollicino, T., additional, Licata, A., additional, Pieri, A., additional, Palitti, V. Pace, additional, Bruzzone, B., additional, Micheli, V., additional, Bertoli, A., additional, Baiocchi, L., additional, Callegaro, A.P., additional, Pellicelli, A., additional, Morisco, F., additional, Gulminetti, R., additional, Novati, S., additional, Lichtner, M., additional, Mastroianni, C., additional, Di Lorenzo, F., additional, Andreone, P., additional, Rossetti, B., additional, Marenco, S., additional, Taliani, G., additional, Boeri, E., additional, Hasson, H., additional, Monno, L., additional, Nicolini, L.A., additional, Landonio, S., additional, Paternoster, C., additional, Puoti, M., additional, Babudieri, S., additional, Quartini, M., additional, Iapadre, N., additional, Cozzolongo, R., additional, Sangiovanni, V., additional, Parruti, G., additional, Sarmati, L., additional, Coppola, N., additional, Baldanti, F., additional, Marco, V. Di, additional, Zazzi, M., additional, Raimondo, G., additional, Angelico, M., additional, Perno, C.F., additional, Andreoni, M., additional, Craxì, A., additional, and Ceccherini-Silberstein, F., additional

Published
2020
Full Text
View/download PDF

18. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

Author

Di Maio, V.C., primary, Aragri, M., additional, Masetti, C., additional, Paolucci, S., additional, Bruzzone, B., additional, Degasperi, E., additional, Barbaliscia, S., additional, Pollicino, T., additional, Minichini, C., additional, Calvaruso, V., additional, Rendina, M., additional, Cento, V., additional, Teti, E., additional, Micheli, V., additional, Allice, T., additional, Polilli, E., additional, Palitti, V. Pace, additional, Landonio, S., additional, Lenci, I., additional, Francioso, S., additional, Donnarumma, L., additional, Nicolini, L.A., additional, Bertoli, A., additional, Starace, M., additional, Pasquazzi, C., additional, Callegaro, A.P., additional, Morisco, F., additional, Cenderello, G., additional, Marenco, S., additional, Gulminetti, R., additional, Novati, S., additional, Scuteri, A., additional, Andreone, P., additional, Galli, S., additional, Ciancio, A., additional, Sangiovanni, V., additional, Cuomo, N., additional, Raddi, A., additional, Gennari, W., additional, Boeri, E., additional, Morsica, G., additional, Hasson, H., additional, Borghi, V., additional, Maida, I., additional, Brunetto, M., additional, Colombatto, P., additional, Cozzolongo, R., additional, De Santis, A., additional, Lichtner, M., additional, Babudieri, S., additional, Biliotti, E., additional, Taliani, G., additional, Santantonio, T., additional, Di Stefano, M., additional, Paternoster, C., additional, Ganga, R., additional, Merli, M., additional, Rizzardini, G., additional, Pellicelli, A., additional, Giannelli, V., additional, Milano, E., additional, Mastroianni, C., additional, Licata, A., additional, Di Lorenzo, F., additional, Giorgini, A., additional, Sighinolfi, L., additional, Dentone, C., additional, Lleo, A., additional, Rossetti, B., additional, Beretta, I., additional, Cariti, G., additional, Ghisetti, V., additional, Lampertico, P., additional, Parruti, G., additional, Coppola, N., additional, Baldanti, F., additional, Gaeta, G.B., additional, Raimondo, G., additional, Puoti, M., additional, Zazzi, M., additional, Andreoni, M., additional, Angelico, M., additional, Perno, C.F., additional, Craxì, A., additional, and Ceccherini-Silberstein, F., additional

Published
2020
Full Text
View/download PDF

20. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

Author

Redi, D., Rossetti, B., Di Maio, V. C., Aragri, M., Paolucci, S., Masetti, C., Paglicci, L., Bruzzone, B., Minichini, C., FRANCESCA MONTAGNANI, Micheli, V., Landonio, S., Degasperi, E., Giacomo Zanelli, Maserati, R., Maida, I., Callegaro, A. P., Barbaliscia, S., Bertoli, A., Paternoster, C., Marenco, S., Morisco, F., Calvaruso, V., Taliani, G., Puoti, M., Cenderello, G., Santis, A., Lichtner, M., Coppola, N., Gulminetti, R., Cento, V., Rendina, M., Teti, E., Parruti, G., Ruggiero, T., Ghisetti, V., Pasquazzi, C., Nicolini, L. A., Vullo, V., Pellicelli, A., Prestileo, T., Cozzolongo, R., Sangiovanni, V., Biolato, M., Lenci, I., Licata, A., Ciaccio, A., Pace Palitti, V., Giorgini, A., Cariti, G., Ciancio, A., Aghemo, A., Borghi, V., Andreone, P., Brunetto, M., Pollicino, T., Santantonio, T., Cuomo, N., Caudai, C., Babudieri, S., Lampertico, P., Gaeta, G. B., Raimondo, G., Andreoni, M., Rizzardini, G., Angelico, M., Perno, C. F., Craxì, A., Maurizio Zazzi, Ceccherini- Silberstein, F., and on behalf of HCV Virology Italian Resistance Network (Vironet C)

Published
2019

22. Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma

Author

Pollicino, T, Musolino, C, Saitta, C, Tripodi, G, Lanza, M, Raffa, G, Tocco, F, Raggi, C, Bragazzi, M, Barbera, A, Navarra, G, Invernizzi, P, Alvaro, D, Raimondo, G, Pollicino, Teresa, Musolino, Cristina, Saitta, Carlo, Tripodi, Gianluca, Lanza, Marika, Raffa, Giuseppina, Tocco, Francesca Casuscelli di, Raggi, Chiara, Bragazzi, Maria Consiglia, Barbera, Adalberto, Navarra, Giuseppe, Invernizzi, Pietro, Alvaro, Domenico, Raimondo, Giovanni, Pollicino, T, Musolino, C, Saitta, C, Tripodi, G, Lanza, M, Raffa, G, Tocco, F, Raggi, C, Bragazzi, M, Barbera, A, Navarra, G, Invernizzi, P, Alvaro, D, Raimondo, G, Pollicino, Teresa, Musolino, Cristina, Saitta, Carlo, Tripodi, Gianluca, Lanza, Marika, Raffa, Giuseppina, Tocco, Francesca Casuscelli di, Raggi, Chiara, Bragazzi, Maria Consiglia, Barbera, Adalberto, Navarra, Giuseppe, Invernizzi, Pietro, Alvaro, Domenico, and Raimondo, Giovanni

Abstract

There is evidence that chronic hepatitis B virus (HBV) infection is associated with an increased risk of intrahepatic cholangiocarcinoma (ICC) development, and it has been hypothesized an etiological role of HBV in the development of this tumor. Very little is known about occult HBV infection (OBI) in ICC. Aims of the study were to investigate the OBI prevalence and to characterize the HBV molecular status at intrahepatic level in OBI-positive cases with ICC. Frozen liver tumor specimens from 47 HBV surface-antigen-negative patients with ICC and 41 paired non-tumor liver tissues were tested for OBI by 4 different HBV-specific nested PCR. Covalently closed circular HBV DNA (HBV cccDNA) and viral integrations were investigated in OBI-positive cases. HBV DNA was detected in tumor and/or non-tumor specimens from 29/47 (61.7%) ICC patients. HBV cccDNA was found in tissues from 5/17 (34.5%) cases examined. HBV integration was detected in 4/10 (40%) tumor tissues tested and involved HBx and HBV-core gene sequences in 3 and 1 cases, respectively. Viral integration occurred: (a) 9,367 nucleotides upstream of the cat-eye-syndrome critical region protein-5-isoform coding sequence; (b) within the cystinosin isoform-1-precursor gene; (c) within the thromboxane-A-synthase-1 gene; (d) within the ATPase phospholipid transporting 9B gene. Occult HBV infection is highly prevalent in patients with ICC. Both free viral genomes and integrated HBV DNA can be present in these cases. These results suggest an involvement of HBV in the carcinogenic process leading to ICC development even in cases with occult infection.

Published
2019

23. AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF)

Author

Burra, P, Rodríguez-Castro, K, Guarino, M, Morisco, F, Villa, E, Mazzella, G, Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) (Alisi, A, Balsano, C, Bernabucci, V, Berzigotti, A, Brunetto, M, Bugianesi, E, Calvaruso, V, Cariani, E, Coco, B, Colle, I, Critelli, R, De Martin, E, Del Buono, M, Fabregat, I, Faillaci, F, Fattovich, G, Floreani, A, Garcia-Tsao, G, Housset, C, Karampatou, A, Lei, B, Mangia, A, Martinez-Chantar, Ml, Milosa, F, Nasta, P, Ozben, T, Pollicino, T, Ponti, Ml, Pontisso, P, Reeves, H, Rendina, M, Rodríguez-Castro, Ki, Sagnelli, C, Sebastiani, Giulia, Smedile, A, Taliani, G, Vandelli, C, Vanni, E, Vukotic, R, Zignego, Al), Alisi A, Balsano C, Bernabucci V, Berzigotti A, Brunetto M, Bugianesi E, Burra P, Calvaruso V, Cariani E, Coco B, Colle I, Critelli R, De Martin E, Del Buono M, Fabregat I, Faillaci F, Fattovich G, Floreani A, Garcia-Tsao G, Housset C, Karampatou A, Lei B, Mangia A, Martinez-Chantar ML, Milosa F, Morisco F, Nasta P, Ozben T, Pollicino T, Ponti ML, Pontisso P, Reeves H, Rendina M, Rodríguez-Castro KI, Sagnelli C, Sebastiani G, Smedile A, Taliani G, Vandelli C, Vanni E, Villa E, Vukotic R, Zignego AL, Burra P, Rodríguez-Castro K, Guarino M, Morisco F, Villa E, Mazzella G., Alisi, A, Balsano, C, Bernabucci, V, Berzigotti, A, Brunetto, M, Bugianesi, E, Burra, P, Calvaruso, V, Cariani, E, Coco, B, Colle, I, Critelli, R, De Martin, E, Del Buono, M, Fabregat, I, Faillaci, F, Fattovich, G, Floreani, A, Garcia-Tsao, G, Housset, C, Karampatou, A, Lei, B, Mangia, A, Martinez-Chantar, Ml, Milosa, F, Morisco, F, Nasta, P, Ozben, T, Pollicino, T, Ponti, Ml, Pontisso, P, Reeves, H, Rendina, M, Rodríguez-Castro, Ki, Sagnelli, C, Sebastiani, G, Smedile, A, Taliani, G, Vandelli, C, Vanni, E, Vukotic, R, Zignego, Al, Rodríguez-Castro, K, Guarino, M, Villa, E, Mazzella, G., Garcia Tsao, G, Martinez Chantar, Ml, Morisco, Filomena, Rodríguez Castro, Ki, Rodríguez Castro, K, Guarino, Maria, Alisi, Anna, Balsano, Clara, Bernabucci, Veronica, Berzigotti, Annalisa, Brunetto, Maurizia, Bugianesi, Elisabetta, Burra, Patrizia, Calvaruso, Vincenza, Cariani, Elisabetta, Coco, Barbara, Colle, Isabelle, Critelli, Rosina, De Martin, Eleonora, Del Buono, Mariagrazia, Fabregat, Isabel, Faillaci, Francesca, Fattovich, Giovanna, Floreani, Annarosa, Garcia-tsao, Guadalupe, Housset, Chantal, Karampatou, Aimilia, Lei, Barbara, Mangia, Alessandra, Martinez-chantar, Maria Luz, Milosa, Fabiola, Nasta, Paola, Ozben, Tomri, Pollicino, Teresa, Ponti, Maria Laura, Pontisso, Patrizia, Reeves, Helen, Rendina, Maria, Rodrã­guez-castro, Kryssia Isabel, Sagnelli, Caterina, Sebastiani, Giada, Smedile, Antonella, Taliani, Gloria, Vandelli, Carmen, Vanni, Ester, Villa, Erica, Vukotic, Ranka, Zignego, Anna Linda, Rodrã­guez-castro, Kryssia, and Mazzella, Giuseppe

Subjects
Risk Assessment, Fertility, Immunosuppression, Liver transplantation, Pregnancy, Immunosuppressive Agent, Medical, Hepatology, Gastroenterology, Humans, Obstetric Labor Complication, Societies, Medical, Postpartum Period, Pregnancy Outcome, Contraception, Female, Italy, Obstetric Labor Complications, Practice Guidelines as Topic, Pregnancy Complications, Immunosuppressive Agents, Liver Transplantation, Pregnancy Complication, surgical procedures, operative, Societies, Human
Abstract

After the first successful pregnancy in a liver transplant recipient in 1978, much evidence has accumulated on the course, outcomes and management strategies of pregnancy following liver transplantation. Generally, liver transplantation restores sexual function and fertility as early as a few months after transplant. Considering that one third of all liver transplant recipients are women, that approximately one-third of them are of reproductive age (18-49 years), and that 15% of female liver transplant recipients are paediatric patients who have a >70% probability of reaching reproductive age, the issue of pregnancy after liver transplantation is rather relevant, and obstetricians, paediatricians, and transplant hepatologists ever more frequently encounter such patients. Pregnancy outcomes for both the mother and infant in liver transplant recipients are generally good, but there is an increased incidence of preterm delivery, hypertension/preeclampsia, foetal growth restriction, and gestational diabetes, which, by definition, render pregnancy in liver transplant recipients a high-risk one. In contrast, the risk of congenital anomalies and the live birth rate are comparable to those of the general population. Currently there are still no robust guidelines on the management of pregnancies after liver transplantation. The aim of this position paper is to review the available evidence on pregnancy in liver transplant recipients and to provide national Italian recommendations for clinicians caring for these patients. (C) 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Published
2016

28. Current epidemiology of HCV in Sicily: the RESIST-HCV model

Author

Di Marco, V., primary, Cartabellotta, F., additional, Mazzucco, W., additional, Calvaruso, V., additional, Petta, S., additional, Mazzola, S., additional, Cusimano, R., additional, Amodio, R., additional, Scifo, G., additional, Russello, M., additional, Cacopardo, B., additional, Squadrito, G., additional, Raimondo, G., additional, Pollicino, T., additional, Ceccherini-Silbertein, F., additional, Vitale, F., additional, Cammà, C., additional, and Craxì, A., additional

Published
2019
Full Text
View/download PDF

29. Second-generation DAAs for HCV: real-life efficacy in the RESIST-HCV cohort

Author

Cacciola, I., primary, Petta, S., additional, Calvaruso, V., additional, Cartabellotta, F., additional, Distefano, M., additional, Scifo, G., additional, Di Lorenzo, F., additional, Sanfilippo, A., additional, Di Rosolini, M.A., additional, Davì, A., additional, Benanti, F., additional, Cacopardo, B., additional, Licata, A., additional, Giannitrapani, L., additional, Cannavò, M.R., additional, Russello, M., additional, Madonia, S., additional, Bavetta, M.G., additional, Digiacomo, A., additional, Averna, A., additional, Alaimo, G., additional, Larocca, L., additional, Bertino, G., additional, Bronte, F., additional, Guarneri, L., additional, Scalisi, I., additional, Iacobello, C., additional, Colletti, P., additional, Portelli, V., additional, Pollicino, T., additional, Ceccherini-Silberstein, F., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2019
Full Text
View/download PDF

30. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

Author

Di Maio, V.C., primary, Aragri, M., additional, Masetti, C., additional, Paolucci, S., additional, Bruzzone, B., additional, Degasperi, E., additional, Barbaliscia, S., additional, Pollicino, T., additional, Minichini, C., additional, Calvaruso, V., additional, Rendina, M., additional, Cento, V., additional, Teti, E., additional, Micheli, V., additional, Ghisetti, V., additional, Polilli, E., additional, Palitti, V. Pace, additional, Landonio, S., additional, Lenci, I., additional, Donnarumma, L., additional, Nicolini, L.A., additional, Bertoli, A., additional, Starace, M., additional, Pasquazzi, C., additional, Callegaro, A.P., additional, Morisco, F., additional, Cenderello, G., additional, Marenco, S., additional, Gulminetti, R., additional, Novati, S., additional, Guarneri, V., additional, Andreone, P., additional, Galli, S., additional, Ciancio, A., additional, Sangiovanni, V., additional, Cuomo, N., additional, Raddi, A., additional, Morsica, G., additional, Borghi, V., additional, Maida, I., additional, Brunetto, M., additional, Colombatto, P., additional, Cozzolongo, R., additional, De Santis, A., additional, Lichtner, M., additional, Babudieri, S., additional, Taliani, G., additional, Santantonio, T., additional, Di Stefano, M., additional, Paternoster, C., additional, Ganga, R., additional, Puoti, M., additional, Rizzardini, G., additional, Pellicelli, A., additional, Milano, E., additional, Mastroianni, C., additional, Licata, A., additional, Di Lorenzo, F., additional, Giorgini, A., additional, Lampertico, P., additional, Parruti, G., additional, Coppola, N., additional, Zazzi, M., additional, Raimondo, G., additional, Andreoni, M., additional, Craxì, A., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2019
Full Text
View/download PDF

34. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing

Author

Ruggiero, T., primary, Cento, V., additional, Aragri, M., additional, Arosio, M., additional, Baldanti, F., additional, Brunetto, M., additional, Bruzzone, B., additional, Boeri, E., additional, Cavallone, D., additional, Nicola, C., additional, Stefano, M.A.D., additional, Ghisetti, V., additional, Callegaro, M.P., additional, Capobianchi, M.R., additional, Caudai, C., additional, Cuomo, N., additional, Galli, S., additional, Galmozzi, E., additional, Garbuglia, A., additional, Gennari, W., additional, Lai, A., additional, Menzo, S., additional, Micheli, V., additional, Minosse, C., additional, Monno, L., additional, Paolucci, S., additional, Pollicino, T., additional, Raddi, A., additional, Raffa, G., additional, Raimondo, G., additional, Sanguinetti, M., additional, Santangelo, R., additional, Santantonio, T., additional, Soldini, S., additional, Starace, M., additional, Vatteroni, M.L., additional, Craxi, A., additional, Perno, C.F., additional, Silberstein, F.C., additional, and Zazzi, M., additional

Published
2018
Full Text
View/download PDF

36. Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy

Author

Maio, V.C.D., primary, Barbaliscia, S., additional, Teti, E., additional, Lenci, I., additional, Aragri, M., additional, Polilli, E., additional, Fiorentino, G., additional, Palitti, V.P., additional, Bruzzone, B., additional, Paolucci, S., additional, Nicola, C., additional, Ruggiero, T., additional, Pollicino, T., additional, Niero, F., additional, Micheli, V., additional, Nicolini, L.A., additional, Marenco, S., additional, Bertoli, A., additional, Maida, I.R., additional, Francioso, S., additional, Foroghi, L., additional, Calvaruso, V., additional, Morisco, F., additional, Lleo, A., additional, Boccaccio, V., additional, Ciancio, A., additional, Maserati, R., additional, Puoti, M., additional, Zazzi, M., additional, Rossetti, B., additional, Vullo, V., additional, D'ambrosio, R., additional, Boglione, L., additional, Bonora, S., additional, Babudieri, S., additional, Gubertini, G.A., additional, Rendina, M.G., additional, Pellicelli, A., additional, Sangiovanni, V., additional, Ciaccio, A., additional, Taliani, G., additional, Raimondo, G., additional, Gaeta, G.B., additional, Craxi, A., additional, Pasquazzi, C., additional, Sarmati, L., additional, Parruti, G., additional, Angelico, M., additional, Andreoni, M., additional, Cento, V., additional, Perno, C.F., additional, and Silberstein, F.C., additional

Published
2018
Full Text
View/download PDF

37. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

Author

Barbaliscia, S., primary, Di Maio, V.C., additional, Teti, E., additional, Lenci, I., additional, Aragri, M., additional, Polilli, E., additional, Fiorentino, G., additional, Pace Palitti, V., additional, Bruzzone, B., additional, Paolucci, S., additional, Coppola, N., additional, Ruggiero, T., additional, Pollicino, T., additional, Niero, F., additional, Micheli, V., additional, Nicolini, L.A., additional, Marenco, S., additional, Bertoli, A., additional, Maida, I., additional, Francioso, S., additional, Foroghi, L., additional, Calvaruso, V., additional, Morisco, F., additional, Lleo, A., additional, Boccaccio, V., additional, Ciancio, A., additional, Maserati, R., additional, Puoti, M., additional, Zazzi, M., additional, Rossetti, B., additional, Vullo, V., additional, D’Ambrosio, A.R., additional, Boglione, L., additional, Bonora, S., additional, Babudieri, S., additional, Gubertini, G., additional, Rendina, M., additional, Pellicelli, A., additional, Sangiovanni, V., additional, Ciaccio, A., additional, Taliani, G., additional, Raimondo, G., additional, Gaeta, G.B., additional, Craxì, A., additional, Pasquazzi, C., additional, Sarmati, L., additional, Parruti, G., additional, Angelico, M., additional, Andreoni, M., additional, Cento, V., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2018
Full Text
View/download PDF

38. Characterization of HBV integration landscape in tumor and non-tumor liver tissues by a high-throughput viral integration detection method

Author

D’Aliberti, D., primary, Giosa, D., additional, Raffa, G., additional, Musolino, C., additional, Tripodi, G., additional, Lombardo, D., additional, Casuscelli di Tocco, F., additional, Saitta, C., additional, Romeo, O., additional, Navarra, G., additional, Raimondo, G., additional, and Pollicino, T., additional

Published
2018
Full Text
View/download PDF

39. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting

Author

Prati, D, Gasbarrini, A, Mazzotta, F, Sagnelli, E, Carosi, G, Abrescia, N, Alberti, Alfredo, Ambu, S, Andreone, P, Andriulli, A, Angelico, M, Antonucci, G, Ascione, A, Belli, Ls, Bruno, R, Bruno, S, Burra, Patrizia, Camma, C, Caporaso, N, Cariti, G, Cillo, U, Coppola, N, Craxi, A, DE LUCA, A, DE MARTIN, E, DI MARCO, V, Fagiuoli, S, Ferrari, C, Gaeta, Gb, Galli, M, Grieco, A, Grossi, P, Licata, A, Maida, I, Mangia, A, Marino, N, Maserati, R, Missale, G, Mondelli, M, Nasta, P, Niro, G, Persico, M, Petrelli, E, Picciotto, A, Piscaglia, F, Pollicino, T, Puoti, C, Puoti, M, Raimondo, G, Rumi, Mg, Santantonio, T, Smedile, A, Squadrito, G, Baroni, Gs, Taliani, G, Tavio, M, Toti, M, Bonino, F, Brunetto, Mr, Cacopardo, B, Caremani, M, Cauda, R, Colombo, M, DI PERRI, G, Donato, F, Farci, P, Fattovich, G, Filice, G, Ghinelli, F, Guadagnino, V, Lazzarin, A, Levrero, M, Licata, G, Orani, A, Paffetti, A, Pastore, G, Piccinino, F, Pizzigallo, E, Pontisso, Patrizia, Portelli, V, Rizzetto, M, Rossi, A, Stroffolini, T, Ubaldi, E, Santantanio, T, Alberti, A., Antonucci, Gf, Craxi, A., Prati D, Gasbarrini A, Mazzotta F, Sagnelli E, Carosi G, Abrescia N, Alberti A, Ambu S, Andreone P, Andriulli A, Angelico M, Antonucci GF, Ascione A, Belli LS, Bruno R, Bruno S, Burra P, Cammà, C, Caporaso N, Cariti G, Cillo U, Coppola N, Craxì, A, De Luca A, De Martin E, Di Marco, V, Fagiuoli S, Ferrari C, Gaeta GB, Galli M, Grieco A, Grossi P, Licata, A, Maida I, Mangia A, Marino N, Maserati R, Missale G, Mondelli M, Nasta P, Niro G, Persico M, Petrelli E, Picciotto A, Piscaglia F, Pollicino T, Prati D, Puoti C, Puoti M, Raimondo G, Rumi MG, Sagnelli E, Santantonio T, Smedile A, Squadrito G, Baroni GS, Taliani G, Tavio M, Toti M, Bonino F, Brunetto MR, Cacopardo B, Caremani M, Cauda R, Colombo M, Di Perri G, Donato F, Farci P, Fattovich G, Filice G, Ghinelli F, Guadagnino V, Lazzarin A, Levrero M, Licata G, Orani A, Paffetti A, Pastore G, Piccinino F, Pizzigallo E, Pontisso P, Portelli V, Rizzetto M, Rossi A, Stroffolini T, Ubaldi E., Italian Association for the Study of the Liver, Italian Society of Infectious, Tropical Disease, Italian Society for the Study of Sexually Transmitted Diseases: Prati D., Gasbarrini A., Mazzotta F., Sagnelli E., Carosi G., Abrescia N., Alberti A., Ambu S., Andreone P., Andriulli A., Angelico M., Antonucci G.F., Ascione A., Belli L.S., Bruno R., Bruno S., Burra P., Cammà C., Caporaso N., Cariti G., Cillo U., Coppola N., Craxì A., De Luca A., De Martin E., Di Marco V., Fagiuoli S., Ferrari C., Gaeta G.B., Galli M., Grieco A., Grossi P., Licata A., Maida I., Mangia A., Marino N., Maserati R., Missale G., Mondelli M., Nasta P., Niro G., Persico M., Petrelli E., Picciotto A., Piscaglia F., Pollicino T., Puoti C., Puoti M., Raimondo G., Rumi M.G., Santantonio T., Smedile A., Squadrito G., Baroni G.S., Taliani G., Tavio M., Toti M., Bonino F., Brunetto M.R., Cacopardo B., Caremani M., Cauda R., Colombo M., Di Perri G., Donato F., Farci P., Fattovich G., Filice G., Ghinelli F., Guadagnino V., Lazzarin A., Levrero M., Licata G., Orani A., Paffetti A., Pastore G., Piccinino F., Pizzigallo E., Pontisso P., Portelli V., Rizzetto M., Rossi A., Stroffolini T., Ubaldi E., Prati, D, Gasbarrini, A, Mazzotta, F, Sagnelli, E, Carosi, G, Abrescia, N, Alberti, A, Ambu, S, Andreone, P, Andriulli, A, Angelico, M, Antonucci, G, Ascione, A, Belli, L, Bruno, R, Bruno, S, Burra, P, Caporaso, N, Cariti, G, Cillo, U, Coppola, N, De Luca, A, De Martin, E, Fagiuoli, S, Ferrari, C, Gaeta, G, Galli, M, Grieco, A, Grossi, P, Maida, I, Mangia, A, Marino, N, Maserati, R, Missale, G, Mondelli, M, Nasta, P, Niro, G, Persico, M, Petrelli, E, Picciotto, A, Piscaglia, F, Pollicino, T, Puoti, C, Puoti, M, Raimondo, G, Rumi, M, Santantonio, T, Smedile, A, Squadrito, G, Baroni, G, Taliani, G, Tavio, M, Toti, M, Bonino, F, Brunetto, M, Cacopardo, B, Caremani, M, Cauda, R, Colombo, M, Di Perri, G, Donato, F, Farci, P, Fattovich, G, Filice, G, Ghinelli, F, Guadagnino, V, Lazzarin, A, Levrero, M, Licata, G, Orani, A, Paffetti, A, Pastore, G, Piccinino, F, Pizzigallo, E, Pontisso, P, Portelli, V, Rizzetto, M, Rossi, A, Stroffolini, T, and Ubaldi, E

Subjects
Liver Cirrhosis, ANTIVIRAL TREATMENT, Human immunodeficiency virus (HIV), HIV Infections, Hepacivirus, ANTIVIRAL THERAPY, PEGYLATED INTERFERON-ALPHA-2B, LIVER-TRANSPLANTATION, PEGINTERFERON ALPHA-2A, HIV-INFECTED PATIENTS, VIRUS-COINFECTED PATIENTS, RAPID VIROLOGICAL RESPONSE, Antiviral therapy, medicine.disease_cause, Gastroenterology, Polyethylene Glycols, HBV, guidelines, Acute hepatitis, Chronic hepatitis, Settore MED/12 - Gastroenterologia, liver transplantation, Hepatitis C, Recombinant Proteins, acute hepatitis, antiviral therapy, chronic hepatitis, cirrhosis, elderly patients, hbv, hcv, hdv, hiv, CLINICAL PRACTICE GUIDELINES, Cirrhosis, HCV, Drug Therapy, Combination, Antiviral therapy Acute hepatitis Chronic hepatitis,Cirrhosis, Elderly patients, HBV, HCV, HDV, HIV Liver transplantation, Elderly patient, Acute hepatiti, medicine.medical_specialty, Genotype, Alpha interferon, Interferon alpha-2, CHRONIC HEPATITIS C, Antiviral Agents, Hepatitis B, Chronic, Internal medicine, HDV, Drug Resistance, Viral, Ribavirin, medicine, Humans, Cirrhosi, Hepatology, business.industry, Settore MED/09 - MEDICINA INTERNA, Interferon-alpha, HIV, Hepatitis C, Chronic, medicine.disease, Elderly patients, Family medicine, Expert opinion, Chronic hepatiti, business
Abstract

It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.

Published
2010

40. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy

Author

Di Maio, V.C., primary, Barbaliscia, S., additional, Lenci, I., additional, Teti, E., additional, Antonucci, F.P., additional, Cento, V., additional, Aragri, M., additional, Paolucci, S., additional, Bruzzone, B., additional, Coppola, N., additional, Ruggiero, T., additional, Pollicino, T., additional, Polilli, E., additional, Pasquazzi, C., additional, Pace Palitti, V., additional, Magni, C.F., additional, Micheli, V., additional, Di Biagio, A., additional, Sticchi, L., additional, Melis, M., additional, Francioso, S., additional, Masetti, C., additional, Foroghi, L., additional, Sarrecchia, C., additional, Baiocchi, L., additional, Landonio, S., additional, Bertoli, A., additional, Calvaruso, V., additional, Morisco, F., additional, Maida, I., additional, Marenco, S., additional, Leo, A., additional, Ghisetti, V., additional, Ciancio, A., additional, Sacchi, P., additional, Novati, S., additional, Brancaccio, G., additional, Pieri, A., additional, Puoti, M., additional, Toniutto, P., additional, Vullo, V., additional, Aghemo, A., additional, Di Perri, G., additional, Babudieri, S., additional, Rizzardini, G., additional, Bruno, S., additional, Pellicelli, A., additional, Taliani, G., additional, Raimondo, G., additional, Baldanti, F., additional, Gaeta, G.B., additional, Craxì, A., additional, Parruti, G., additional, Andreoni, M., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2017
Full Text
View/download PDF

41. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

Author

Di Maio, V.C., primary, Cento, V., additional, Lenci, I., additional, Aragri, M., additional, Barbaliscia, S., additional, Francioso, S., additional, Paolucci, S., additional, Melis, M., additional, Verucchi, G., additional, Masetti, C., additional, Coppola, N., additional, Magni, C.F., additional, Micheli, V., additional, Pollicino, T., additional, Ruggiero, T., additional, Landonio, S., additional, Mancon, A., additional, Starace, M., additional, De Leonardis, F., additional, Santopaolo, F., additional, Bertoli, A., additional, Antonucci, F.P., additional, D’Ambrosio, C., additional, Calvaruso, V., additional, Sorbo, M.C., additional, Morisco, F., additional, Pasquazzi, C., additional, Maida, I., additional, Picciotto, A., additional, Di Biagio, A., additional, Bruzzone, B., additional, Sticchi, L., additional, Ghisetti, V., additional, Cozzolongo, R., additional, Romagnoli, D., additional, Boccaccio, V., additional, Grieco, A., additional, Vecchiet, J., additional, D’Ettorre, G., additional, Merli, M., additional, Gaeta, G.B., additional, Ciancio, A., additional, Marinaro, L., additional, Polilli, E., additional, Cacciatore, P., additional, Andreone, P., additional, Barbarini, G., additional, Gulminetti, R., additional, Novati, S., additional, Pace Palitti, V., additional, Tarquini, P., additional, Puoti, M., additional, Sangiovanni, V., additional, De Stefano, G., additional, Giorgini, A., additional, Paoloni, M., additional, Caporaso, N., additional, Babudieri, S., additional, Gubertini, G., additional, Bruno, S., additional, Andreoni, M., additional, Pellicelli, A., additional, Parruti, G., additional, Raimondo, G., additional, Baldanti, F., additional, Rizzardini, G., additional, Craxì, A., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2017
Full Text
View/download PDF

42. Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies

Author

Di Maio, V.C., primary, Cento, V., additional, Lenci, I., additional, Aragri, M., additional, Barbaliscia, S., additional, Francioso, S., additional, Paolucci, S., additional, Melis, M., additional, Verucchi, G., additional, Coppola, N., additional, Magni, C.F., additional, Micheli, V., additional, Pollicino, T., additional, Ruggiero, T., additional, Santopaolo, F., additional, Landonio, S., additional, Mancon, A., additional, Starace, M., additional, Bertoli, A., additional, Antonucci, F.P., additional, D’Ambrosio, C., additional, Calvaruso, V., additional, Morisco, F., additional, Pasquazzi, C., additional, Maida, I., additional, Picciotto, A., additional, Biagio, A.D., additional, Bruzzone, B., additional, Sticchi, L., additional, Ghisetti, V., additional, Cozzolongo, R., additional, Romagnoli, D., additional, Boccaccio, V., additional, Grieco, A., additional, Vecchiet, J., additional, D’Ettorre, G., additional, Merli, M., additional, Gaeta, G.B., additional, Ciancio, A., additional, Marinaro, L., additional, Andreone, P., additional, Barbarini, G., additional, Gulminetti, R., additional, Palitti, V.P., additional, Tarquini, P., additional, Puoti, M., additional, Sangiovanni, V., additional, Stefano, G.D., additional, Giorgini, A., additional, Paoloni, M., additional, Caporaso, N., additional, Babudieri, S., additional, Gubertini, G., additional, Bruno, S., additional, Andreoni, M., additional, Pellicelli, A., additional, Parruti, G., additional, Raimondo, G., additional, Baldanti, F., additional, Craxì, A., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2017
Full Text
View/download PDF

45. Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy

Author

Cacciola, I, Messineo, F, Cacopardo, B, DI MARCO, Vito, Galli, C, Squadrito, G, Musolino, C, Saitta, C, Pollicino, T, Raimondo, G., Cacciola, I, Messineo, F, Cacopardo, B, Di Marco, V, Galli, C, Squadrito, G, Musolino, C, Saitta, C, Pollicino, T, and Raimondo, G

Subjects
HEV
Published
2011

46. Micro-RNA segnature of human hepatocellular carcinoma

Author

PEDICONI N, VOSSIO S, POLLICINO T, CERVELLO M, LEVRERO M., MONTALTO, Giuseppe, RAIMONDO, Giovanni, PEDICONI N, VOSSIO S, POLLICINO T, MONTALTO G, CERVELLO M, RAIMONDO G, and LEVRERO M

Published
2008

47. Statements from the Taormina expert meeting on occult hepatitis B virus infection

Author

RAIMONDO G., ALLAIN J., BRUNETTO M., BUENDIA M., CHEN D., COLOMBO M., CRAXI A., DONATO F., GERLICH W., LEVRERO M., LOCARNINI S., MICHALAK T., MONDELLI M., PAWLOTSKY J., POLLICINO T., PRATI D., PUOTI M., SAMUEL D., SHOUVAL D., SMEDILE A., SQUADRITO G., TREPO C., VILLA E., WILL H., ZANETTI A., ZOULIM F., GAETA, Giovanni Battista, Raimondo, G., Allain, J., Brunetto, M., Buendia, M., Chen, D., Colombo, M., Craxi, A., Donato, F., Gaeta, Giovanni Battista, Gerlich, W., Levrero, M., Locarnini, S., Michalak, T., Mondelli, M., Pawlotsky, J., Pollicino, T., Prati, D., Puoti, M., Samuel, D., Shouval, D., Smedile, A., Squadrito, G., Trepo, C., Villa, E., Will, H., Zanetti, A., and Zoulim, F.

Abstract

Occult HBV infection is a complex biological entity with possible relevant clinical implications. There are discordant data sets on several aspects of OBI, mainly reflecting the lack of methodological uniformity among the different studies, and varied technical approaches employed for the diagnosis of OBI. The goal of the Taormina meeting was to review the present knowledge on occult HBV and to identify the most appropriate ways that should be followed in future studies. Hopefully, these statements may represent the basis for uniform methodological approaches that will be essential for resolving the current controversies that still exist with regard to this virologically important and clinically relevant topic.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results